Ozomet-G 1 Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 1 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, functions by stimulating pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving peripheral glucose uptake, and enhancing insulin sensitivity. The synergistic action of these two agents helps achieve better glycemic control in patients inadequately managed by diet, exercise, or monotherapy. Ozomet-G 1 Tablet PR is typically prescribed as part of a comprehensive diabetes management plan, including lifestyle modifications such as diet and physical activity. It is important to monitor blood glucose levels regularly and adjust dosage based on therapeutic response and tolerance. Caution is advised in patients with renal or hepatic impairment, cardiovascular disease, or a history of lactic acidosis. Common adverse effects may include gastrointestinal disturbances, hypoglycemia, and, rarely, lactic acidosis. This medication should be used under medical supervision, with periodic assessment of renal function and blood glucose to optimize treatment efficacy and safety.